ADVB
Advanced Biomed Inc.
Price Chart
Latest Quote
$4.17
-0.34 (-7.54%)
Current Price
| Previous Close | $4.51 |
| Open | $4.27 |
| Day High | $4.39 |
| Day Low | $4.14 |
| Volume | 6,394 |
Stock Information
| Shares Outstanding | 1.65M |
| Total Debt | $713K |
| Cash Equivalents | $2.61M |
| Net Income | $4.76M |
| Sector | Healthcare |
| Industry | Diagnostics & Research |
| Market Cap | $6.89M |
| P/E Ratio | 1.04 |
| EPS (TTM) | $4.00 |
| Exchange | NCM |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $3.86M |
| Income | $4.76M |
| Book/sh | $6.66 |
| Cash/sh | $1.58 |
| Employees | 31 |
Financial Ratios
| Quick Ratio | 1.90 |
| Current Ratio | 7.38 |
| Debt/Eq | 7.74 |
Returns & Margins
| ROA | -21.50% |
| ROE | 71.33% |
Ownership
| Insider Ownership | 45.96% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| P/B | 0.63 |
Analyst Data
| Recommendation | none |
Technical Indicators
| SMA20 | $4.50 |
| SMA50 | $5.13 |
| SMA200 | $6.80 |
| RSI | 46.13 |
| ATR | 0.5464 |
| Shares Float | 630K |
| Short Float | 0.37% |
| Short Ratio | 0.01 |
| Rel Volume | 0.20 |
Performance History
| Week | -16.77% |
| Month | -38.50% |
| Quarter | -6.50% |
| 6 Months | -46.54% |
| YTD | -30.96% |
| Year | -78.26% |
| 10 Years | -94.29% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-05 | $4.17 | 6,394 |
| 2026-06-04 | $4.26 | 10,100 |
| 2026-06-03 | $4.39 | 9,700 |
| 2026-06-02 | $4.41 | 17,000 |
| 2026-06-01 | $4.39 | 53,300 |
| 2026-05-29 | $5.01 | 286,900 |
| 2026-05-28 | $3.91 | 12,800 |
| 2026-05-27 | $3.88 | 14,900 |
| 2026-05-26 | $3.98 | 3,600 |
| 2026-05-22 | $3.95 | 7,600 |
| 2026-05-21 | $4.13 | 10,700 |
| 2026-05-20 | $4.44 | 47,000 |
| 2026-05-19 | $4.42 | 3,900 |
| 2026-05-18 | $4.57 | 7,200 |
| 2026-05-15 | $4.40 | 13,600 |
| 2026-05-14 | $4.43 | 13,200 |
| 2026-05-13 | $4.75 | 29,000 |
| 2026-05-12 | $5.23 | 16,100 |
| 2026-05-11 | $5.01 | 25,600 |
| 2026-05-08 | $6.19 | 38,700 |
| 2026-05-07 | $7.20 | 63,000 |
| 2026-05-06 | $6.78 | 86,900 |
About Advanced Biomed Inc.
Advanced Biomed Inc., an investment holding company, engages in the research and development of microfluidic biochip technologies for precision oncology detection, diagnosis, and treatment in Taiwan. Its devices include A+Pre, an automated sample preparation system that enables pre-concentration of diluted blood samples; AC-1000, a rare cell device to solve the problem of detection of hypercoagulable state samples of tumor patients; A+SCDrop, a circulating tumor cell (CTC) single-cell capture device; and A+CellScan, an analyzer with an immunostaining chip for immunostaining/analysis of the AC-1000 product. The company also offers microfluidic biochips, such as A+Pre, AC-1000 CTC enrichment, and A+CellScan chips to provide assay products and services to cancer patients. In addition, its immunochromogenic kits include A+CTCE kit to identify epithelial circulating tumor cells and determined by the immunochromogenicity of EpCAM, CK (pan), CD45, and CD14 antibodies; A+CTCM kit to identify mesenchymal circulating tumor cells based on the immunochromogenicity of Vimentin, CD45, and CD14 antibodies; A+EMT to identify epithelial-to-mesenchymal circulating tumor cells determined by the immunochromogenicity of cell-surface Vimentin, and CD45 and CD14 antibodies; and A+CM to identify tumor-associated macrophages based on the immunochromogenicity of PD-L1, CD45, and CD14 antibodies. Further, the company is developing A+LCGuard for early screening of lung cancer. Additionally, it establishes and operates medical clinics in the People's Republic of China. The company was founded in 2014 and is headquartered in New York, New York.
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | - | $0 | $0 | $0 |
| Operating Revenue | - | $0 | $0 | $0 |
| Expenses | ||||
| Total Expenses | - | $2,541,572 | $3,071,223 | $2,374,371 |
| Other Income Expense | - | $-294,201 | $-682,956 | $-1,653,594 |
| Other Non Operating Income Expenses | - | $486 | $-21,111 | $-35,620 |
| Net Non Operating Interest Income Expense | - | $53,495 | $21,402 | $243 |
| Operating Expense | - | $2,541,572 | $3,071,223 | $2,374,371 |
| General And Administrative Expense | - | $1,261,777 | $1,322,811 | $624,774 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | - | $-2,782,278 | $-3,732,777 | $-4,027,722 |
| Net Interest Income | - | $53,495 | $21,402 | $243 |
| Interest Income | - | $53,495 | $21,402 | $243 |
| Normalized Income | - | $-2,487,591 | $-3,070,932 | $-2,409,748 |
| Net Income From Continuing And Discontinued Operation | - | $-2,782,278 | $-3,732,777 | $-4,027,722 |
| Net Income Common Stockholders | - | $-2,782,278 | $-3,732,777 | $-4,027,722 |
| Net Income | - | $-2,782,278 | $-3,732,777 | $-4,027,722 |
| Net Income Including Noncontrolling Interests | - | $-2,782,278 | $-3,732,777 | $-4,027,722 |
| Net Income Continuous Operations | - | $-2,782,278 | $-3,732,777 | $-4,027,722 |
| Pretax Income | - | $-2,782,278 | $-3,732,777 | $-4,027,722 |
| Special Income Charges | - | $0 | $-150,207 | $-1,617,974 |
| Interest Income Non Operating | - | $53,495 | $21,402 | $243 |
| Operating Income | - | $-2,541,572 | $-3,071,223 | $-2,374,371 |
| Depreciation Amortization Depletion Income Statement | - | $399,602 | $365,231 | $130,066 |
| Depreciation And Amortization In Income Statement | - | $399,602 | $365,231 | $130,066 |
| Per Share | ||||
| Diluted EPS | $-3.20 | $-2.57 | $-3.45 | $-0.64 |
| Basic EPS | $-3.20 | $-2.57 | $-3.45 | $-0.64 |
| Other | ||||
| Diluted Average Shares | $1,026,284 | $1,082,000 | $6,250,000 | $6,250,000 |
| Basic Average Shares | $1,026,284 | $1,082,000 | $6,250,000 | $6,250,000 |
| Tax Effect Of Unusual Items | - | $0 | $0 | $0 |
| Tax Rate For Calcs | - | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | - | $-1,847,283 | $-2,044,147 | $-626,331 |
| Total Unusual Items | - | $-294,687 | $-661,845 | $-1,617,974 |
| Total Unusual Items Excluding Goodwill | - | $-294,687 | $-661,845 | $-1,617,974 |
| Reconciled Depreciation | - | $399,602 | $365,231 | $126,632 |
| EBITDA (Bullshit earnings) | - | $-2,141,970 | $-2,705,992 | $-2,244,305 |
| EBIT | - | $-2,541,572 | $-3,071,223 | $-2,374,371 |
| Diluted NI Availto Com Stockholders | - | $-2,782,278 | $-3,732,777 | $-4,027,722 |
| Tax Provision | - | $0 | $0 | $0 |
| Gain On Sale Of Business | - | $0 | $-150,207 | - |
| Gain On Sale Of Security | - | $-294,687 | $-511,638 | - |
| Research And Development | - | $880,193 | $1,383,181 | $1,619,531 |
| Selling General And Administration | - | $1,261,777 | $1,322,811 | $624,774 |
| Other Gand A | - | $500,520 | $579,520 | $313,463 |
| Salaries And Wages | - | $761,257 | $743,291 | $311,311 |
| Impairment Of Capital Assets | - | - | $0 | $1,617,974 |
Fetched: 2026-06-03
Balance Sheet (Annual)
| Metric | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | - | $1,544,260 | $1,055,267 | $3,080,797 |
| Total Assets | - | $4,460,247 | $4,599,977 | $6,713,499 |
| Total Non Current Assets | - | $1,409,137 | $1,813,989 | $1,707,788 |
| Other Non Current Assets | - | $-1 | $56,127 | $71,021 |
| Non Current Deferred Assets | - | $638,871 | $553,471 | $0 |
| Goodwill And Other Intangible Assets | - | $118,998 | $250,321 | $410,799 |
| Other Intangible Assets | - | $118,998 | $250,321 | $410,799 |
| Current Assets | - | $3,051,110 | $2,785,988 | $5,005,711 |
| Prepaid Assets | - | $237,960 | $13,759 | $59,329 |
| Receivables | - | $205,177 | $149,950 | $162,518 |
| Receivables Adjustments Allowances | - | $0 | $0 | $0 |
| Other Receivables | - | $44,035 | $3,325 | $23,469 |
| Taxes Receivable | - | $161,142 | $146,625 | $139,049 |
| Cash Cash Equivalents And Short Term Investments | - | $2,607,973 | $2,622,279 | $4,783,864 |
| Cash And Cash Equivalents | - | $2,607,973 | $2,622,279 | $4,783,864 |
| Cash Financial | - | $2,607,973 | $2,622,279 | $4,783,864 |
| Debt | ||||
| Total Debt | - | $126,740 | $235,373 | $468,868 |
| Long Term Debt And Capital Lease Obligation | - | $64,529 | $18,806 | $232,191 |
| Current Debt And Capital Lease Obligation | - | $62,211 | $216,567 | $236,677 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | - | $2,796,989 | $3,294,389 | $3,221,903 |
| Total Non Current Liabilities Net Minority Interest | - | $64,529 | $18,806 | $232,191 |
| Current Liabilities | - | $2,732,460 | $3,275,583 | $2,989,712 |
| Payables And Accrued Expenses | - | $2,670,249 | $3,059,016 | $2,753,035 |
| Payables | - | $2,670,249 | $3,059,016 | $2,753,035 |
| Other Payable | - | $1,261,699 | $769,717 | $1,990,833 |
| Accounts Payable | - | $620,476 | $632,820 | $762,202 |
| Equity | ||||
| Common Stock Equity | - | $1,663,258 | $1,305,588 | $3,491,596 |
| Total Equity Gross Minority Interest | - | $1,663,258 | $1,305,588 | $3,491,596 |
| Stockholders Equity | - | $1,663,258 | $1,305,588 | $3,491,596 |
| Gains Losses Not Affecting Retained Earnings | - | $1,123,344 | $804,020 | $268,859 |
| Other Equity Adjustments | - | $1,123,344 | $804,020 | $268,859 |
| Retained Earnings | - | $-15,974,075 | $-13,191,797 | $-9,459,020 |
| Other | ||||
| Ordinary Shares Number | $1,082,000 | $1,082,000 | $1,082,000 | $1,082,000 |
| Share Issued | $1,082,000 | $1,082,000 | $1,082,000 | $1,082,000 |
| Tangible Book Value | - | $1,544,260 | $1,055,267 | $3,080,797 |
| Invested Capital | - | $1,663,258 | $1,305,588 | $3,491,596 |
| Working Capital | - | $318,650 | $-489,595 | $2,015,999 |
| Capital Lease Obligations | - | $126,740 | $235,373 | $468,868 |
| Total Capitalization | - | $1,663,258 | $1,305,588 | $3,491,596 |
| Additional Paid In Capital | - | $16,493,989 | $13,673,365 | $12,582,757 |
| Capital Stock | - | $20,000 | $20,000 | $99,000 |
| Common Stock | - | $20,000 | $20,000 | $99,000 |
| Long Term Capital Lease Obligation | - | $64,529 | $18,806 | $232,191 |
| Current Capital Lease Obligation | - | $62,211 | $216,567 | $236,677 |
| Dueto Related Parties Current | - | $788,074 | $1,656,479 | $0 |
| Net PPE | - | $651,269 | $954,070 | $1,225,968 |
| Accumulated Depreciation | - | $-1,230,457 | $-996,371 | $-805,624 |
| Gross PPE | - | $1,881,726 | $1,950,441 | $2,031,592 |
| Leases | - | $201,516 | $201,994 | $212,078 |
| Other Properties | - | $1,613,132 | $1,681,900 | $1,754,713 |
| Machinery Furniture Equipment | - | $67,078 | $66,547 | $64,801 |
| Properties | - | $0 | $0 | $0 |
Fetched: 2026-06-03
Cash Flow Statement (Annual)
| Metric | 2024-06-30 | 2023-06-30 | 2022-06-30 | 2021-06-30 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-2,200,450 | $-3,176,148 | $-2,053,580 | $-499,417 |
| Operating Activities | ||||
| Operating Cash Flow | $-2,126,340 | $-2,963,625 | $-741,450 | $-473,975 |
| Cash Flow From Continuing Operating Activities | $-2,126,340 | $-2,963,625 | $-741,450 | $-473,975 |
| Operating Gains Losses | - | $150,207 | $37,634 | - |
| Investing Activities | ||||
| Capital Expenditure | $-74,110 | $-212,523 | $-1,312,130 | $-25,442 |
| Investing Cash Flow | $-74,110 | $-263,009 | $-1,083,684 | $-25,442 |
| Cash Flow From Continuing Investing Activities | $-74,110 | $-263,009 | $-1,083,684 | $-25,442 |
| Financing Activities | ||||
| Issuance Of Capital Stock | $0 | $1,011,608 | $6,097,131 | $697,164 |
| Financing Cash Flow | $1,866,820 | $458,137 | $6,097,131 | $697,164 |
| Cash Flow From Continuing Financing Activities | $1,866,820 | $458,137 | $6,097,131 | $697,164 |
| Net Other Financing Charges | $294,900 | $-553,471 | - | - |
| Net Common Stock Issuance | $-85,400 | $1,011,608 | $6,097,131 | $697,164 |
| Common Stock Issuance | $0 | $1,011,608 | $6,097,131 | $697,164 |
| Other | ||||
| Issuance Of Debt | $1,657,320 | $0 | - | - |
| Interest Paid Supplemental Data | $0 | $0 | $0 | $0 |
| Income Tax Paid Supplemental Data | $0 | $0 | $0 | $0 |
| End Cash Position | $2,607,973 | $2,622,279 | $4,783,864 | $65,922 |
| Beginning Cash Position | $2,622,279 | $4,783,864 | $65,922 | $65,705 |
| Effect Of Exchange Rate Changes | $319,324 | $606,912 | $445,945 | $-197,530 |
| Changes In Cash | $-333,630 | $-2,768,497 | $4,271,997 | $197,747 |
| Net Issuance Payments Of Debt | $1,657,320 | $0 | - | - |
| Net Long Term Debt Issuance | $1,657,320 | $0 | - | - |
| Long Term Debt Issuance | $1,657,320 | $0 | - | - |
| Net Business Purchase And Sale | $0 | $-50,486 | $199,527 | $0 |
| Sale Of Business | $0 | - | $199,527 | $0 |
| Net Intangibles Purchase And Sale | $0 | $-1,640 | $-422,536 | $0 |
| Purchase Of Intangibles | $0 | $-1,640 | $-422,536 | $0 |
| Net PPE Purchase And Sale | $-74,110 | $-210,883 | $-860,675 | $-25,442 |
| Purchase Of PPE | $-74,110 | $-210,883 | $-889,594 | $-25,442 |
| Interest Received Cfo | $53,495 | $21,402 | $243 | $28 |
| Change In Working Capital | $256,336 | $253,714 | $1,504,032 | $1,305,333 |
| Change In Other Current Liabilities | $0 | $-25,973 | $25,973 | $0 |
| Change In Other Current Assets | $56,127 | $14,894 | $0 | - |
| Change In Payables And Accrued Expense | $479,634 | $381,253 | $912,424 | $17,238 |
| Change In Payable | $479,634 | $381,253 | $912,424 | $17,238 |
| Change In Account Payable | $479,634 | $381,253 | $912,424 | $17,238 |
| Change In Prepaid Assets | $-279,425 | $-116,460 | $565,635 | $1,288,095 |
| Change In Receivables | $53,495 | $21,402 | $243 | $28 |
| Other Non Cash Items | $-53,495 | $-21,402 | $-243 | $-28 |
| Depreciation Amortization Depletion | $399,602 | $365,231 | $126,632 | $57,850 |
| Depreciation And Amortization | $399,602 | $365,231 | $126,632 | $57,850 |
| Amortization Cash Flow | $131,323 | $136,424 | $11,737 | $0 |
| Amortization Of Intangibles | $131,323 | $136,424 | $11,737 | $0 |
| Depreciation | $268,279 | $228,807 | $114,895 | $57,850 |
| Gain Loss On Sale Of Business | $0 | $150,207 | $0 | - |
| Net Income From Continuing Operations | $-2,782,278 | $-3,732,777 | $-4,027,722 | $-1,837,158 |
| Purchase Of Business | - | $-50,486 | $0 | - |
| Sale Of PPE | - | $0 | $28,919 | $0 |
| Asset Impairment Charge | - | $0 | $1,617,974 | $0 |
| Gain Loss On Sale Of PPE | - | $0 | $37,634 | $0 |
Fetched: 2026-06-03